Bristol Myers Squibb Company $BMY Shares Sold by Tufton Capital Management

Tufton Capital Management reduced its holdings in Bristol Myers Squibb Company (NYSE:BMY) by 5.9% during the second quarter, according to the company in its most recent filing with the SEC. The fund owned 73,506 shares of the biopharmaceutical company’s stock after selling 4,575 shares during the quarter. Tufton Capital Management’s holdings in Bristol Myers Squibb were worth $3,402,000 as of its most recent filing with the SEC.

A number of other large investors also recently modified their holdings of the business. Magnolia Capital Advisors LLC lifted its position in shares of Bristol Myers Squibb by 12.9% in the 2nd quarter. Magnolia Capital Advisors LLC now owns 4,491 shares of the biopharmaceutical company’s stock worth $208,000 after buying an additional 514 shares during the last quarter. Code Waechter LLC lifted its position in shares of Bristol Myers Squibb by 57.4% in the 2nd quarter. Code Waechter LLC now owns 12,873 shares of the biopharmaceutical company’s stock worth $596,000 after buying an additional 4,692 shares during the last quarter. Hussman Strategic Advisors Inc. bought a new position in shares of Bristol Myers Squibb in the 2nd quarter worth about $972,000. Freestone Capital Holdings LLC lifted its position in shares of Bristol Myers Squibb by 24.7% in the 2nd quarter. Freestone Capital Holdings LLC now owns 19,488 shares of the biopharmaceutical company’s stock worth $902,000 after buying an additional 3,855 shares during the last quarter. Finally, Wellington Shields Capital Management LLC lifted its position in Bristol Myers Squibb by 5.2% in the 2nd quarter. Wellington Shields Capital Management LLC now owns 5,486 shares of the biopharmaceutical company’s stock valued at $254,000 after purchasing an additional 272 shares during the last quarter. 76.41% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of research analysts have issued reports on BMY shares. Sanford C. Bernstein reiterated a “market perform” rating on shares of Bristol Myers Squibb in a research report on Monday. Weiss Ratings reissued a “hold (c-)” rating on shares of Bristol Myers Squibb in a research note on Tuesday, October 14th. Morgan Stanley restated a “hold” rating on shares of Bristol Myers Squibb in a research report on Thursday, July 31st. Daiwa Capital Markets downgraded shares of Bristol Myers Squibb from an “outperform” rating to a “neutral” rating and set a $42.00 price target on the stock. in a research report on Tuesday, August 5th. Finally, Dbs Bank upgraded shares of Bristol Myers Squibb to a “moderate buy” rating in a research report on Thursday, October 2nd. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and fifteen have assigned a Hold rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $57.23.

Bristol Myers Squibb Stock Down 0.2%

BMY stock opened at $45.96 on Tuesday. The firm’s 50-day moving average is $45.32 and its two-hundred day moving average is $46.76. The company has a market capitalization of $93.55 billion, a price-to-earnings ratio of 18.53, a price-to-earnings-growth ratio of 2.23 and a beta of 0.33. The company has a current ratio of 1.21, a quick ratio of 1.11 and a debt-to-equity ratio of 2.54. Bristol Myers Squibb Company has a 52 week low of $42.52 and a 52 week high of $63.33.

Bristol Myers Squibb (NYSE:BMY) last announced its quarterly earnings data on Thursday, October 30th. The biopharmaceutical company reported $1.63 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.52 by $0.11. The company had revenue of $12.22 billion for the quarter, compared to analysts’ expectations of $11.75 billion. Bristol Myers Squibb had a net margin of 10.58% and a return on equity of 80.04%. The business’s revenue was up 2.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.80 EPS. Bristol Myers Squibb has set its FY 2025 guidance at 6.400-6.600 EPS. On average, analysts forecast that Bristol Myers Squibb Company will post 6.74 earnings per share for the current fiscal year.

Bristol Myers Squibb Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Monday, November 3rd. Stockholders of record on Friday, October 3rd were paid a $0.62 dividend. The ex-dividend date of this dividend was Friday, October 3rd. This represents a $2.48 annualized dividend and a dividend yield of 5.4%. Bristol Myers Squibb’s payout ratio is currently 83.78%.

Insider Activity

In other news, EVP David V. Elkins sold 56,000 shares of Bristol Myers Squibb stock in a transaction that occurred on Tuesday, September 2nd. The shares were sold at an average price of $47.33, for a total value of $2,650,480.00. Following the transaction, the executive vice president owned 167,379 shares of the company’s stock, valued at $7,922,048.07. The trade was a 25.07% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this link. 0.09% of the stock is owned by corporate insiders.

Bristol Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.